keyword
MENU ▼
Read by QxMD icon Read
search

"Health technology assessment"

keyword
https://www.readbyqxmd.com/read/27908281/health-technology-assessment-of-drugs-for-rare-diseases-insights-trends-and-reasons-for-negative-recommendations-from-the-cadth-common-drug-review
#1
REVIEW
Ghayath Janoudi, William Amegatse, Brendan McIntosh, Chander Sehgal, Trevor Richter
BACKGROUND: A shift in biochemical research towards drugs for rare diseases has created new challenges for the pharmaceutical industry, government regulators, health technology assessment agencies, and public and private payers. In this article, we aim to comprehensively review, characterize, identify possible trends, and explore reasons for negative reimbursement recommendations in submissions made to the Common Drug Review (CDR) for drugs for rare diseases (DRD) at the Canadian Agency for Drugs and Technologies in Health (CADTH), a publicly funded pan-Canadian health technology assessment agency...
December 1, 2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27902409/prevention-of-herpes-zoster-and-its-complications-from-the-clinic-to-the-real-life-experience-with-the-vaccine
#2
Giovanni Gabutti, Nicoletta Valente, Parvanè Kuhdari, Silvia Lupi, Armando Stefanati
The Herpes Zoster (HZ) is an acute viral illness characterized by a vesicular rash, with unilateral distribution, which can eventually cause severe complications, such as the post-herpetic neuralgia (PHN), the ophthalmic zoster, stroke or other neurological complications. In Europe, an incidence between 2.0 and 4.6 cases per 1,000 persons-year is estimated, with an increase after 50 years of age. Currently, the therapeutic options for HZ are only partially effective to limit the acute phase, while the management of complications is frequently complex and not satisfactory...
November 4, 2016: Journal of Medical Microbiology
https://www.readbyqxmd.com/read/27899956/innovations-that-reach-the-patient-early-health-technology-assessment-and-improving-the-chances-of-coverage-and-implementation
#3
W H van Harten, V P Retèl
With growing concerns for the sustainability of the financial burden that health care-and especially cancer services-poses on the national budgets, the role of health economic analyses in coverage decisions is likely to grow. One of the strategies for the biomedical research field-also in oncology research-to foster coverage and health system implementation, is to anticipate this new role and to involve health technology assessment techniques earlier in various stages of translational research. In this article, we elaborate on the early involvement of health technology assessment in translational research and the concept of Coverage with Evidence Development in The Netherlands Cancer Institute and give two case examples that are currently ongoing: (1) tumour infiltrating lymphocytes therapy for metastatic melanoma; and (2) high-dose chemotherapy for BRCA1-like subgroup in triple-negative breast cancer...
2016: Ecancermedicalscience
https://www.readbyqxmd.com/read/27899770/-universal-health-coverage-and-cancer-drugs-a-cost-effectiveness-perspective
#4
Ayako Fukuda, Ataru Igarashi
Japanese health system has been evaluated to be the closest to the ideal Universal Health Coverage(UHC)in the world. "Ideal UHC" is to ensure that all people could obtain the health services they need without suffering any financial hardship. However, maintaining current healthcare system, under which all medications are covered, is getting difficult due to the aging society and the existence of high-price drugs such as anti-cancer agents. Approval of OPDIVO(nivolumab)has raised the national discussion in Japan because of the possibility that the use of OPDIVO might collapse overall healthcare system...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27899141/relationship-between-surgeon-volume-and-outcomes-a-systematic-review-of-systematic-reviews
#5
Johannes Morche, Tim Mathes, Dawid Pieper
BACKGROUND: The surgeon volume-outcome relationship has been discussed for many years and its existence or nonexistence is of importance for various reasons. A lot of empirical work has been published on it. We aimed to summarize systematic reviews in order to present current evidence. METHODS: Medline, Embase, Cochrane database of systematic reviews (CDSR), and health technology assessment websites were searched up to October 2015 for systematic reviews on the surgeon volume-outcome relationship...
November 29, 2016: Systematic Reviews
https://www.readbyqxmd.com/read/27897967/an-observational-study-of-donor-ex-vivo-lung-perfusion-in-uk-lung-transplantation-develop-uk
#6
Andrew Fisher, Anders Andreasson, Alexandros Chrysos, Joanne Lally, Chrysovalanto Mamasoula, Catherine Exley, Jennifer Wilkinson, Jessica Qian, Gillian Watson, Oli Lewington, Thomas Chadwick, Elaine McColl, Mark Pearce, Kay Mann, Nicola McMeekin, Luke Vale, Steven Tsui, Nizar Yonan, Andre Simon, Nandor Marczin, Jorge Mascaro, John Dark
BACKGROUND: Many patients awaiting lung transplantation die before a donor organ becomes available. Ex vivo lung perfusion (EVLP) allows initially unusable donor lungs to be assessed and reconditioned for clinical use. OBJECTIVE: The objective of the Donor Ex Vivo Lung Perfusion in UK lung transplantation study was to evaluate the clinical effectiveness and cost-effectiveness of EVLP in increasing UK lung transplant activity. DESIGN: A multicentre, unblinded, non-randomised, non-inferiority observational study to compare transplant outcomes between EVLP-assessed and standard donor lungs...
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27896268/challenges-for-relative-effectiveness-assessment-and-early-access-of-cancer-immunotherapies-in-europe
#7
Mira Pavlovic
Clinical endpoints relevant for relative effectiveness assessment (REA) reflect how patients feel, function, or survive. Outcome data requested by health technology assessment (HTA) bodies in Europe to support reimbursement of an anticancer drug are based on final endpoints coming from completed comparative phase 3 trials; overall survival improvement is the preferred criterion for the demonstration of the patient benefit in this field. Recent arrival of new treatments that target identified functional genetic mutations ("targeted therapies") or PD-1/PD-L1,2 axis ("immunotherapies") and their combinations have profoundly changed treatment strategies in cancers as they considerably improve patient survival, but also raise new challenges in REA and decision-making process in Europe as compared to the REA of "classical" chemotherapies...
2016: Frontiers in Medicine
https://www.readbyqxmd.com/read/27884733/hospital-related-cost-of-sepsis-a-systematic-review
#8
REVIEW
Habibollah Arefian, Steffen Heublein, André Scherag, Frank Martin Brunkhorst, Mustafa Z Younis, Onnen Moerer, Dagmar Fischer, Michael Hartmann
OBJECTIVES: This article systematically reviews research on the costs of sepsis and, as a secondary aim, evaluates the quality of economic evaluations reported in peer-reviewed journals. METHODS: We systematically searched the MEDLINE, National Health Service (Abstracts of Reviews of Effects, Economic Evaluation and Health Technology Assessment), Cost-effectiveness Analysis Registry and Web of Knowledge databases for studies published between January 2005 and June 2015...
November 21, 2016: Journal of Infection
https://www.readbyqxmd.com/read/27884491/impact-of-patient-outcomes-and-cost-aspects-on-reimbursement-recommendations-in-poland-in-2012-2014
#9
Krzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trąbka
The aim of this study was to assess the influence of different factors on the final reimbursement recommendations for drugs in Poland and to identify the correlation between these factors and the probability of a positive reimbursement recommendation for an applicant drug issued by the President of the Agency for Health Technology Assessment and Tariff System (AOTMiT). We analysed all recommendations for the period of 2012-2014 in Poland, three years following the launch of the new Reimbursement Act of Medicines, Foodstuffs Intended for Particular Nutritional Uses and Medical Devices...
October 26, 2016: Health Policy
https://www.readbyqxmd.com/read/27884180/the-impact-of-mhealth-interventions-on-health-systems-a-systematic-review-protocol
#10
Jill Fortuin, Faatiema Salie, Leila H Abdullahi, Tania S Douglas
BACKGROUND: Mobile health (mHealth) has been described as a health enabling tool that impacts positively on the health system in terms of improved access, quality and cost of health care. The proposed systematic review will examine the impact of mHealth on health systems by assessing access, quality and cost of health care as indicators. METHODS: The systematic review will include literature from various sources including published and unpublished/grey literature...
November 25, 2016: Systematic Reviews
https://www.readbyqxmd.com/read/27884175/network-meta-analyses-performed-by-contracting-companies-and-commissioned-by-industry
#11
Ewoud Schuit, John Pa Ioannidis
BACKGROUND: Industry commissions contracting companies to perform network meta-analysis for health technology assessment (HTA) and reimbursement submissions. Our objective was to estimate the number of network meta-analyses performed by consulting companies contracted by industry, to assess whether they were published, and to explore reasons for non-publication. METHODS: We searched MEDLINE for network meta-analyses of randomized trials. Papers were included if they had authors affiliated with any contracting company...
November 25, 2016: Systematic Reviews
https://www.readbyqxmd.com/read/27882823/the-transparency-of-published-health-technology-assessment-based-recommendations-on-pharmaceutical-reimbursement-in-poland
#12
Tomasz Bochenek, Ewa Kocot, Marcin Rodzinka, Brian Godman, Katarzyna Maciejewska, Susan Kamal, Andrzej Pilc
BACKGROUND: The appropriate access to public information is very important for healthcare system stakeholders. OBJECTIVE: The goal of this study was to examine how the execution of the formally existing right to public information on the HTA-based recommendations on reimbursement of new health technologies from public funds has been changing in Poland. METHODS: All recommendations published within two predefined equal periods of time between 2013 and 2015 were analyzed...
November 24, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/27881276/the-development-of-the-romanian-scorecard-hta-system
#13
Ciprian-Paul Radu, Nona Delia Chiriac, Alexandra Mihaela Pravat
OBJECTIVES: To present the characteristics of the scorecard health technology assessment (HTA) implemented since 2014 and to show the results of this HTA process by the end of 2015. METHODS: The health care context and the Romanian HTA legislation were studied while considering the reasons behind HTA introduction, the key stakeholders, and the HTA process as a whole. A critical appraisal was done covering public HTA reports and the decisions made by the Ministry of Health...
September 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27881269/value-of-information-in-asia-concepts-current-use-and-future-directions
#14
Piyameth Dilokthornsakul, R Brett McQueen, Nathorn Chaiyakunapruk, Eldon Spackman, Jonathan H Watanabe, Jonathan D Campbell
Health technology assessment is a form of health policy research that provides policymakers with information relevant to decisions about policy alternatives. Findings from cost-effectiveness analysis (CEA) are one of the important aspects of health technology assessment. Nevertheless, the more advanced method of value of information (VOI), which is recommended by the International Society for Pharmacoeconomics and Outcomes Research and Society for Medical Decision Making Modeling Good Research Practices Task Force, has rarely been applied in CEA studies in Asia...
May 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27881265/importance-of-economic-evaluation-in-health-care-an-indian-perspective
#15
Amit Dang, Nishkarsh Likhar, Utkarsh Alok
Health economic studies provide information to decision makers for efficient use of available resources for maximizing health benefits. Economic evaluation is one part of health economics, and it is a tool for comparing costs and consequences of different interventions. Health technology assessment is a technique for economic evaluation that is well adapted by developed countries. The traditional classification of economic evaluation includes cost-minimization, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis...
May 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27881254/health-technology-assessment-international-reference-pricing-and-budget-control-tools-from-china-s-perspective-what-are-the-current-developments-and-future-considerations
#16
Liling Koh, Christoph Glaetzer, Shu Chuen Li, Meng Zhang
BACKGROUND: China is investing considerably in health care reforms to address issues in its health care system. An example is access to innovative drugs, which remains challenging because it is largely dependent on patient self-pay. Recognizing this, the government has invested considerably in its basic medical insurance. As health care expenditure increases, there are growing concerns on budget control. Several health policy tools have been discussed recently such as health technology assessment, international reference pricing, and hospital budget control tools, which can be viewed as addressing the affordability concerns of the government budget...
May 2016: Value in Health Regional Issues
https://www.readbyqxmd.com/read/27872122/polymyxin-b-immobilised-haemoperfusion-and-mortality-in-critically-ill-patients-with-sepsis-septic-shock-a-protocol-for-a-systematic-review-and-meta-analysis
#17
Tomoko Fujii, Riki Ganeko, Yuki Kataoka, Robin Featherstone, Sean M Bagshaw, Toshi A Furukawa
INTRODUCTION: Polymyxin-B immobilised haemoperfusion (PMX-HP) is a promising adjuvant strategy for the treatment of sepsis and septic shock. PMX-HP therapy works by clearing circulating endotoxin through binding to polymyxin-immobilised fibres during haemoperfusion. Small clinical trials have shown that PMX-HP therapy is associated with improved haemodynamic profile, oxygenation and survival. However, clear inferences have been largely inconclusive due to limitations in study design (eg, small, unblinded) and generalisability...
November 21, 2016: BMJ Open
https://www.readbyqxmd.com/read/27871122/efficacy-and-safety-of-ablation-for-people-with-non-paroxysmal-atrial-fibrillation
#18
REVIEW
Jonathan Nyong, Guy Amit, Alma J Adler, Onikepe O Owolabi, Pablo Perel, David Prieto-Merino, Pier Lambiase, Juan Pablo Casas, Carlos A Morillo
BACKGROUND: The optimal rhythm management strategy for people with non-paroxysmal (persistent or long-standing persistent) atrial fibrilation is currently not well defined. Antiarrhythmic drugs have been the mainstay of therapy. But recently, in people who have not responded to antiarrhythmic drugs, the use of ablation (catheter and surgical) has emerged as an alternative to maintain sinus rhythm to avoid long-term atrial fibrillation complications. However, evidence from randomised trials about the efficacy and safety of ablation in non-paroxysmal atrial fibrillation is limited...
November 22, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27869298/informant-questionnaire-on-cognitive-decline-in-the-elderly-iqcode-for-the-early-diagnosis-of-dementia-across-a-variety-of-healthcare-settings
#19
REVIEW
Jennifer K Harrison, David J Stott, Rupert McShane, Anna H Noel-Storr, Rhiannon S Swann-Price, Terry J Quinn
BACKGROUND: The Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) is a structured interview based on informant responses that is used to assess for possible dementia. IQCODE has been used for retrospective or contemporaneous assessment of cognitive decline. There is considerable interest in tests that may identify those at future risk of developing dementia. Assessing a population free of dementia for the prospective development of dementia is an approach often used in studies of dementia biomarkers...
November 21, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27864208/payer-view-of-personalized-medicine
#20
Edmund J Pezalla
PURPOSE: The process and methods used by payers when evaluating coverage of personalized medicine testing are described. SUMMARY: Personalized medicine encompasses a number of diagnostic tools that measure drug metabolism, genetic risk for disease development, and tumor type or markers that can guide oncology treatments. However, whole genome testing, tumor marker testing, and testing for drug metabolism are additional costs to the healthcare system. In order to justify these costs, payers and health technology assessment bodies must evaluate the individual tests or groups of tests on their own merits...
December 1, 2016: American Journal of Health-system Pharmacy: AJHP
keyword
keyword
9540
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"